CCSA mulls ways to lure tourists as threat wanes

CCSA mulls ways to lure tourists as threat wanes
Travelers visit Suvarnabhumi airport in Samut Prakan province on Sept 1. (Photo: Somchai Poomlard)
Tourists visit Suvarnabhumi airport in Samut Prakan province on September 1 . (Photo: Somchai Poomlard)

The Centre for Covid-19 Situation Administration (CCSA) is considering more measures to promote tourism due to a drop in the number of everyday Covid-19 cases.

Daily cases have started to fall below 1, 500 this month — with 774 new cases reported on Tuesday  — and 10-15 deaths reported on average each day, mouthpiece government spokeswoman Traisuree Taisaranakul said on Tuesday. The country fully reopened to travelers in July.

“The authorities is working on a plan to come up with measures to advertise tourism to accommodate a lot more tourists during the [upcoming] top season, ” the lady said, adding the CCSA will hold a meeting on the matter on Friday.

Meanwhile, the government provides urged everyone, specifically the high-risk “608” group — which comprises people elderly 60 years and above, those with underlying diseases and pregnant women — to complete a two-dose course of vaccines as well as a booster.

Dr Sophon Iamsirithavorn, deputy director-general of the Department of Illness Control (DDC), stated a Long Acting Antibody (LAAB) combination, which usually protects against serious Covid-19, showed it might even treat a 105-year-old patient who was not previously vaccinated but got contaminated with the virus.

Moreover, research in the United States, Europe plus Japan showed the LAAB shots is able to reduce the fatality rate by 50% plus significantly ease symptoms if administered within 3-5 days of individuals contracting the infection, specifically those in susceptible groups, she mentioned.

The particular Committee for Medicinal Products for Human being Use under the Western european Medicines Agency has suggested all countries administer LAAB pictures to patients that are more likely to develop serious symptoms including the elderly, those who suffer immunodeficiency and have underlying diseases.

Japan registered the LAAB on Aug 30 and the European Union is usually expected to approve this soon. It is getting reviewed by the US and Thailand.